• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study backs RejuvenAir treatment for bronchitis from CSA Medical

September 6, 2022 By Sean Whooley

CSA Medical RejuvenAir metered cryosprayCSA Medical announced today that study data support the use of its RejuvenAir system for treating chronic bronchitis.

Boston-based CSA Medical designed its metered cryospray (MCS) treatment using the RejuvenAir System. RejuvenAir, a proprietary interventional liquid nitrogen spray cryotherapy system, utilize software-driven dosimetry and specialty catheter.

Together, this enables the delivery of cryogen spray inside the airways to flash freeze and destroy damaged cells. The company designed it to allow for a rejuvenative pattern of healing.

According to a news release, data came from the first randomized, controlled study of MCS with RejuvenAir for chronic bronchitis. Data was presented by Dr. Christopher Orton (Royal Brompton Hospital, London) at the International Congress of the European Respiratory Society in Barcelona.

Patient-reported symptom scores (measured by SGRQ and CAT) were statistically significant and clinically meaningful, respectively. The sham group of the study saw quality of life continue to decline, CSA said. Sham subjects were offered treatment crossover at six months and all 32 subjects have now completed treatment.

The team at Royal Brompton reported strong safety and clinically meaningful 24-month results from a previous open-label trial. With the new cohort, the team has now performed more than 100 MCS treatments with zero pneumothoraces.

“This first randomized controlled study data reinforces previous feasibility results showing quality of life improvement in patients with chronic bronchitis,” Imperial College (London) professor of respiratory medicine Pallav Shah said. “RejuvenAir metered cryospray is both safe and effective in a patient population with multiple co-morbidities, in a disease with no established therapies.”

CSA is currently enrolling in SPRAY-CB,a pivotal study for RejuvenAir in patients with COPD with chronic bronchitis as well.

Filed Under: Clinical Trials, Drug-Device Combinations, Respiratory Tagged With: CSA Medical

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS